| Document |
Document Title |
|
WO/2023/087632A1 |
The present invention belongs to the field of medicinal chemistry, and specifically disclosed are an anti-inflammatory analgesic compound and the use thereof. The compound of the present invention is a compound having a structure shown i...
|
|
WO/2023/090086A1 |
Provided are a secondary monohydrofluoroalkane selective adduct and a method for producing the same. A compound represented by formula (3) is produced by means of a method including a step for reacting a compound represented by formula (...
|
|
WO/2023/089594A1 |
The present invention relates to tirzepatide or a pharmaceutically acceptable salt thereof. The present invention also relates to a process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof. The present inven...
|
|
WO/2023/090315A1 |
A method for producing acetaminophen, the method comprising passing a p-nitrophenol-containing solution, together with an acetylating agent and hydrogen, through a column packed with a catalyst to thereby cause the p-nitrophenol to under...
|
|
WO/2023/090859A1 |
The present invention relates to: a novel method for preparing an isoxazole derivative, which is useful as a farnesoid X receptor (FXR, NR1H4) agonist; a novel intermediate used in the preparation method; and a method for preparing the p...
|
|
WO/2023/089601A2 |
The invention relates to compounds that inhibit DUBs, particularly USP9X. The invention also includes methods of inhibiting DUBs, including USP9X, and methods of treating cancers.
|
|
WO/2023/083161A1 |
Provided in the present invention are a biphenyl heterocyclic compound, and a synthesis method therefor and the use thereof. The biphenyl heterocyclic compound has the following general formula (I). The synthesis process of the biphenyl ...
|
|
WO/2023/078277A1 |
An intermediate of a polyamine derivative, a preparation method therefor, and a use thereof. The intermediate is easy to prepare and high in purity; and when the intermediate is used for preparing the polyamine derivative, the obtained p...
|
|
WO/2023/077977A1 |
Disclosed are a compound as represented by the figure for the abstract, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are each independently selected from a group composed of H, methyl, ethyl, n-propyl and isopropyl; a...
|
|
WO/2023/070198A1 |
The present technology generally relates to a shampoo in solid form including: a system of surfactants, a system of thickening agents, at least one conditioning agent, a system of preservation agents. The shampoo being reconstitutable to...
|
|
WO/2023/073080A1 |
The present invention relates to a process for preparing aromatic acyl derivatives of formula (I) using methanesulfonic acid. The invention further relates to methods for preparing biological active ingredients, such as paracetamol.
|
|
WO/2023/072143A1 |
Disclosed in the present invention are a camptothecin derivative intermediate, and a preparation method therefor and the use thereof. The structural formula of the camptothecin derivative intermediate of the present invention is as shown...
|
|
WO/2023/066368A1 |
Provide crystalline forms of N- (3, 5-difluorobenzyl) -N-hydroxy-2, 2-dimethylbutanamide, methods of preparing and characterizing the crystalline forms, and methods of using the crystalline forms to treat various diseases or conditions, ...
|
|
WO/2023/061437A1 |
The present invention relates to a salt of an antitumor drug and a crystal form thereof, and specifically relates to a pharmaceutical salt of the compound N-(3-(2-((2-methoxy-4-(4-methyl-1-piperazinyl)phenyl)amino)-
7-oxo-6-phenyl-8(7H)-...
|
|
WO/2023/064493A1 |
This invention provides compounds for the inhibition of papain-like proteases (PLpros) for the inhibition of viruses, including compounds of formula (I"), and pharmaceutically acceptable salts thereof.
|
|
WO/2023/019242A9 |
Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intoler...
|
|
WO/2023/062627A1 |
Provided herein are compounds that inhibit the protein-protein interaction of serine acetyltransferase (SAT) with O-acetyl serine sulfhydrylase (OASS), and can therefore be used as herbicides.
|
|
WO/2023/060955A1 |
Provided in the present invention is a synthetic method for cetyl-PG hydroxyethyl palmitamide. The method comprises the following steps: firstly, mixing 1,3-dichloropropanol and hexadecyl alcohol under the action of a catalyst and an alk...
|
|
WO/2023/054350A1 |
The present invention provides a production method for purified dichloroacetic acid and an efficient production method for nucleic acid molecules using same. Specifically, the present invention provides: a production method for purified ...
|
|
WO/2023/050121A1 |
Disclosed in the present invention are biodegradable glass based on an amino acid, a peptide and a derivative, and a preparation method therefor and an application thereof. A main raw material of the glass is one of or a combination of a...
|
|
WO/2023/053877A1 |
Provided are: a compound suitable for use as a photodisintegrable base for resist compositions which have satisfactory sensitivity to actinic energy, e.g., EB or EUV, have excellent resolution in lithography, and can give fine patterns r...
|
|
WO/2023/054626A1 |
Provided is a cyclopropanamide derivative. A compound represented by formula (1) [wherein: n represents an integer of 0, 1, 2 or 3; ring A represents (1) 4-pyridyl which may be substituted with 1 to 4 substituents, or (2) phenyl which is...
|
|
WO/2023/046882A1 |
There is provided herein compounds of formula I and pharmaceutically acceptable salts thereof, wherein X1, X2, Z, the ring containing Q1 to Q5, m and r have meanings as provided in the description. There is also provided medical uses of ...
|
|
WO/2023/049785A1 |
Described herein are compounds and compositions for use in treatment or prevention of an inflammatory bowel disease, gastrointestinal cancer, or a systemic bacterial infection in a subject in need thereof. They subject may be colonized b...
|
|
WO/2023/045377A1 |
The present invention relates to a novel deuterated PEG lipid compound, a preparation method therefor, and a composition and an application thereof. Specifically disclosed are a novel deuterated lipid compound as shown in formula A and f...
|
|
WO/2023/039941A1 |
Provided are an N,N,N-triacyl-2,4,6-triaminotoluene compound nucleating agent, and a preparation method therefor and a use method thereof. The nucleating agent is used for polymer nucleation at high temperatures, and can effectively redu...
|
|
WO/2023/042715A1 |
A monomer composition for dental materials which includes a (meth)acrylamide compound (A) including a cyclic structure and a (meth)acrylamide group.
|
|
WO/2023/043803A1 |
Disclosed herein are FABP4 and FABP5 inhibitor compounds and their use in pharmaceutical compositions for treating diseases relating to fatty acid metabolism, including cancer. Also disclosed herein are methods for preparing the disclose...
|
|
WO/2023/039940A1 |
Disclosed is a method for preparing N,N,N-tripivaloyl-1,3,5-triaminobenzene. The method comprises: step 1, using 2,4,6-trinitrotoluene as a raw material, and reacting same with hydrogen and pivalic anhydride in sequence to obtain N,N,N-t...
|
|
WO/2023/040106A1 |
Disclosed in the present invention is a preparation method for an acetamide compound by means of green visible-light catalysis. In the method, LED lamps are used as light sources to provide energy, and economically available aromatic ami...
|
|
WO/2023/042716A1 |
A production method for a (meth)acrylamide compound that includes a step for reacting (meth)acrylic acid with a primary amine compound in the presence of a condensing agent to synthesize a (meth)acrylamide compound (X).
|
|
WO/2023/043038A1 |
The present invention provides a novel compound for a capping layer, and an organic light-emitting device comprising same.
|
|
WO/2023/043039A1 |
The present invention provides a novel compound for a light-emitting device, and an organic light-emitting device comprising same.
|
|
WO/2022/272036A9 |
The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
|
|
WO/2023/038093A1 |
Provided is a deuterium-enriched composition comprising a deuterium-substituted carboxylic acid or a salt thereof, wherein the carboxylic acid or the salt thereof includes an α hydrogen of a carboxy group and a hydrogen other than the Î...
|
|
WO/2023/034510A1 |
Provided herein is a process for the preparation of 3,4-methylenedioxymethamphetamine, (R)-3,4-methylenedioxymethamphetamine and (S)-3,4-methylenedioxymethamphetamine.
|
|
WO/2023/033055A1 |
This fluorine-containing ether compound is represented by the following formula: R1-R2-CH2-R3[-CH2-R4-CH2-R3']n-CH2-R5-R6 (n represents 1 or 2, R3 and R3' each represent a perfluoropolyether chain, R4 represents a divalent linkage group ...
|
|
WO/2023/033044A1 |
Provided is a fluorine-containing ether compound represented by the following formula. R1-[B]-[A]-O-CH2-R2-CH2-O-[C]-[D]-R3 (wherein, R1 denotes a C7-18 organic group including a group in which an aromatic hydrocarbon and a nitrogen atom...
|
|
WO/2023/024511A1 |
Provided is a lipid compound represented by formula (I), which can be used alone, or can be used in combination with other lipid components such as neutral lipids, steroids and/or analogs thereof, and/or polymer-conjugated lipids, so as ...
|
|
WO/2023/025854A1 |
The present invention relates to malonamide compounds of the formula (I) where the variables are as defined in the claims and the description, and to compositions comprising these compounds. The invention also relates to the use of said ...
|
|
WO/2023/025855A1 |
The present invention relates to malonamide compounds of the formula (I) where the variables are as defined in the claims and the description, and to compositions comprising these compounds. The invention also relates to the use of said ...
|
|
WO/2023/025138A1 |
Disclosed are novel exatecan mesylate intermediates 5 and A, and a preparation method for exatecan mesylate. Raw materials in the preparation method are cheap and easy to obtain, the synthetic route of the intermediate is simple, the "on...
|
|
WO/2023/023288A1 |
Provided herein are inhibitors of GPX4, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the GPX4 inhibitory compounds for the modulation of ferroptosis and treatment of disease.
|
|
WO/2023/020531A1 |
A method for synthesizing 5,8-diamino-3,4-dihydro-2H-1-naphthalenone (compound I), which method comprises: subjecting 2,5-diprotected aminophenylbutyric acid to the Friedel-Crafts reaction for ring closure, and then removing a protecting...
|
|
WO/2023/022155A1 |
The present invention provides a polymer-dispersed liquid crystal element which is provided with a liquid crystal alignment film that achieves high adhesion between a polymer liquid crystal layer and a base material, while having a high ...
|
|
WO/2023/017269A1 |
The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: (I) wherein RA and RB are as defined herein.
|
|
WO/2023/014050A1 |
The present invention relates to a method for efficiently recovering dimethylformamide at high purity from a waste solution resulting from the production of a polyimide. The method according to the present invention is directed to a meth...
|
|
WO/2023/011596A1 |
A compound of formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical composition containing them, and their use as a selective androgen receptor degradation (SARD) agent and/or androgen receptor (AR)...
|
|
WO/2023/005567A1 |
The present invention is related to a composition and its application in controlled living water-based emulsion polymerization. The composition comprises at least one organic water-soluble iodine compound, optionally at least one organic...
|
|
WO/2023/009785A1 |
The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
|
